Your session is about to expire
← Back to Search
Sitravatinib for Renal Cell Carcinoma
Study Summary
This trial will study if the combination of sitravatinib and nivolumab is effective in treating patients with locally-advanced clear cell renal cell carcinoma before surgery.
- Clear Cell Renal Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 25 Patients • NCT03680521Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the deleterious effects associated with Sitravatinib in patients?
"Sitravatinib attained a safety rating of 2, as the Phase 2 trial has been able to provide proof that it is relatively safe but there is no evidence yet showing its efficacy."
Is this trial a pioneering effort in its field?
"Since 2012, the pharmaceutical industry has been conducting research into sitravatinib. Initially sponsored by Ono Pharmaceutical Co Ltd., an initial trial was conducted in 2012 involving 659 people which followed with Phase 1 and 2 drug approval. Presently, there are 728 clinical trials for sitravatinib spread across 2366 cities in 49 countries worldwide."
What conditions is Sitravatinib typically used to treat?
"Sitravatinib is typically used to combat malignant neoplasms, but it has also been proven effective in treating conditions such as metastatic esophageal adenocarcinoma, squamous cell carcinoma, and unresectable melanoma."
Could you summarize any other research efforts surrounding Sitravatinib?
"Currently, the number of active studies related to Sitravatinib stands at 728 with 83 in Phase 3. Basel, BE is home to many trials for this medication and globally there are 40,413 sites conducting research on its efficacy."
Are there any openings available for prospective participants in this clinical trial?
"Unfortunately, this medical trial is no longer actively accepting participants; the last update was on April 27th 2021. However, there are currently 2580 trials looking for individuals with carcinoma and 728 studies recruiting patients that require Sitravatinib treatment."
What is the cap on participants for this clinical research?
"This clinical trial is no longer actively seeking participants. Originally registered on October 10th 2018, the study was last updated April 27th 2021. Carcinoma and renal cell patients have a multitude of other options with 2580 active trials while those searching for Sitravatinib can join one of 728 studies currently recruiting."
Share this study with friends
Copy Link
Messenger